Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14564100 | 0.90 | ALDH1A1 (0.41) | ALDH1A1 | |
| SCHEMBL1703329 | 0.88 | ALDH1A1 (0.42) | ALDH1A1 | |
| SCHEMBL28677838 | 0.81 | LMNA (0.55) | ALDH1A1BLMLMNATSHR | |
| SCHEMBL4276516 | 0.78 | ALDH1A1 (0.48) | ALDH1A1TSHRACE2 | |
| SCHEMBL5674121 | 0.77 | TSHR (0.39) | ALDH1A1TSHR | |
| SCHEMBL11764667 | 0.77 | TSHR (0.39) | ALDH1A1LMNATSHR | |
| SCHEMBL31603488 | 0.76 | FFAR4 (0.42) | BLMLMNATSHRFFAR4ACE2 | |
| SCHEMBL4275817 | 0.76 | OPRM1 (0.44) | ALDH1A1LMNATSHRACE2 | |
| SCHEMBL20298309 | 0.74 | TSHR (0.39) | BLMLMNATSHRFFAR4ACE2 | |
| SCHEMBL3964951 | 0.74 | LMNA (0.52) | ALDH1A1BLMLMNAACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170326172-A1 | Sachet Formulation for Amine Polymers | GENZYME CORPORATION (US) | 2017-11-16 | — | — | US | disclosed |
| US-20160158275-A1 | PHARMACEUTICAL COMPOSITIONS | GENZYME CORPORATION | 2016-06-09 | — | — | US | disclosed |
| US-20130243720-A1 | Iron(II)-Containing A Treatments for Hyperphosphatemia | HUVAL CHAD (US) | 2013-09-19 | — | — | US | disclosed |
| US-8187634-B2 | Process for the preparation of sevelamer hydrochloride and formulation thereof | USV, LTD. (IN) | 2012-05-29 | — | — | US | disclosed |
| US-7846425-B2 | Process for the preparation of sevelamer hydrochloride and formulation thereof | USV, LTD. (IN) | 2010-12-07 | — | — | US | disclosed |
| US-20100305302-A1 | METHOD OF DRYING A MATERIAL HAVING A COHESIVE PHASE | MAGINATICS LLC | 2010-12-02 | — | — | US | disclosed |
| US-20100092421-A1 | Process for the Preparation of Sevelamer Hydrochloride and Formulation Thereof | USV PRIVATE LIMITED (IN) | 2010-04-15 | — | — | US | disclosed |
| US-20090304623-A1 | Once A Day Formulation for Phosphate Binders | GENZYME CORPORATION (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090280178-A1 | Process for the Preparation of Sevelamer Hydrochloride and Formulation Thereof | USV PRIVATE LIMITED (IN) | 2009-11-12 | — | — | US | disclosed |
| US-20090155368-A1 | Pharmaceutical compositions | GENZYME CORPORATION (US) | 2009-06-18 | — | — | US | disclosed |
| US-20070190135-A1 | Phosphate-binding polymer and tablets using the same | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158275-A1 | PHARMACEUTICAL COMPOSITIONS | SRM, PHPT1, PTH1R | ALDH1A1 2918/4885BLM 1012/4885LMNA 2699/4885 |
| US-20170326172-A1 | Sachet Formulation for Amine Polymers | PHPT1, PSPH, SOST | ALDH1A1 3220/4885BLM 1865/4885LMNA 3517/4885 |
| US-20130243720-A1 | Iron(II)-Containing A Treatments for Hyperphosphatemia | SLC20A2, PFKFB2, SLC46A1 | ALDH1A1 1175/4885BLM 4751/4885LMNA 4624/4885 |
| US-20100092421-A1 | Process for the Preparation of Sevelamer Hydrochloride and Formulation Thereof | DPP4, PDE9A, SI | ALDH1A1 3583/4885BLM 2673/4885LMNA 4436/4885 |
| US-20090155368-A1 | Pharmaceutical compositions | SRM, PHPT1, PTH1R | ALDH1A1 2918/4885BLM 1012/4885LMNA 2699/4885 |
| US-20090280178-A1 | Process for the Preparation of Sevelamer Hydrochloride and Formulation Thereof | DPP4, PDE9A, SI | ALDH1A1 3583/4885BLM 2673/4885LMNA 4436/4885 |
| US-20090304623-A1 | Once A Day Formulation for Phosphate Binders | PHPT1, SLC34A2, SLC34A1 | ALDH1A1 3591/4885BLM 2387/4885LMNA 3815/4885 |
| US-20070190135-A1 | Phosphate-binding polymer and tablets using the same | PYGM, PYGB, GYS1 | ALDH1A1 4812/4885BLM 3577/4885LMNA 4563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.